Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Mark C. Petrie(British Heart Foundation), Eric J. Velazquez(Yale University), Pardeep S. Jhund(Copenhagen University Hospital), Alexander Romanov(Medical University of Vienna), Łukasz Chrzanowski(Medical University of Lodz), Krzysztof S. Gołba(Mount Sinai Hospital), Christopher Adlbrecht, Peter E. Carson(Inserm), Julio A. Panza(MedStar Washington Hospital Center), Harvey D. White(University of Auckland), David Prior(St Vincent's Hospital Melbourne), Lilin She(Clinical Research Institute), Alan B. Miller(Touro University California), James A. Hill(Fred Hutch Cancer Center), Maddury Jyotsna(Medical University of Vienna), Jean L. Rouleau(Montreal Heart Institute), Imtiaz S. Ali(University of Calgary), Kerry L. Lee(Clinical Research Institute), Torsten Doenst(Jena University Hospital)
Cited by 168
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k